Citations (34)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Yang Lo & Tsen-Fang Tsai. (2021) Updates on the Treatment of Erythrodermic Psoriasis. Psoriasis: Targets and Therapy 11, pages 59-73.
Read now
Read now
Vidhi V. Shah, Erica B. Lee, Shivani Reddy, Elaine J. Lin & Jashin J. Wu. (2018) Comparison of guidelines for the use of TNF inhibitors for psoriasis in the United States, Canada, Europe and the United Kingdom: a critical appraisal and comprehensive review. Journal of Dermatological Treatment 29:6, pages 586-592.
Read now
Read now
Rasnik K Singh, Kristina M Lee, Derya Ucmak, Merrick Brodsky, Zaza Atanelov, Benjamin Farahnik, Michael Abrouk, Mio Nakamura, Tian Hao Zhu & Wilson Liao. (2016) Erythrodermic psoriasis: pathophysiology and current treatment perspectives. Psoriasis: Targets and Therapy 6, pages 93-104.
Read now
Read now
Andrew A. Nelson, Daniel J. Pearce, Alan B. Fleischer Jr, Rajesh Balkrishnan & Steven R. Feldman. (2005) Infliximab for inpatient psoriasis management – is there a role?. Journal of Dermatological Treatment 16:5-6, pages 314-318.
Read now
Read now
Articles from other publishers (30)
Suman Rao, Michelle Bernshteyn, Raman Sohal, Rachael Proumen, Alexandra Goodman & Zachary Shepherd. (2020) The Management of Erythrodermic Psoriasis Complicated by Cyclosporine. Case Reports in Dermatological Medicine 2020, pages 1-3.
Crossref
Crossref
Osward Y. Carrasquillo, Gabriela Pabón-Cartagena, Leyre A. Falto-Aizpurua, Marely Santiago-Vázquez, Karina J. Cancel-Artau, Gabriel Arias-Berrios & Rafael F. Martín-García. (2020) Treatment of erythrodermic psoriasis with biologics: A systematic review. Journal of the American Academy of Dermatology 83:1, pages 151-158.
Crossref
Crossref
Laura Pizzatti, Cristina Mugheddu, Silvia Sanna, Laura Atzori & Franco Rongioletti. (2020) Erythrodermic psoriasis in a dialyzed patient successfully treated with Secukinumab. Dermatologic Therapy 33:3.
Crossref
Crossref
Shuai Shao, Gang Wang, Emanual Maverakis & Johann E. Gudjonsson. (2020) Targeted Treatment for Erythrodermic Psoriasis: Rationale and Recent Advances. Drugs 80:6, pages 525-534.
Crossref
Crossref
Geetha Krishnamoorthy, Aditya Kotecha & Jason Pimentel. (2019) Complete resolution of erythrodermic psoriasis with first-line apremilast monotherapy. BMJ Case Reports 12:1, pages e226959.
Crossref
Crossref
Francisco Kerdel & Martin Zaiac. (2015) An evolution in switching therapy for psoriasis patients who fail to meet treatment goals. Dermatologic Therapy 28:6, pages 390-403.
Crossref
Crossref
Giuseppe Stinco & Enzo Errichetti. (2015) Erythrodermic Psoriasis: Current and Future Role of Biologicals. BioDrugs 29:2, pages 91-101.
Crossref
Crossref
John Koo, Ethan Levin, Argentina Leon, Jashin Wu & Alice GottliebEthan Levin, Eric Sako, Shannon Famenini & Jashin Wu. 2014. Moderate to Severe Psoriasis, Fourth Edition. Moderate to Severe Psoriasis, Fourth Edition
277
288
.
Lucía Campos Muñoz, Blanca de Unamuno Bustos, Pedro Herranz Pinto, Husein Husein El Ahmed, Ricardo Ruiz-Villaverde & Rosa Taberner Ferrer. (2014) Infliximab Treatment of Psoriasis in Supervised Infusion Centers: Case Management Experience. American Journal of Clinical Dermatology 15:S1, pages 17-24.
Crossref
Crossref
Bruce E. Strober, Jennifer Clay Cather, David Cohen, Jeffrey J. Crowley, Kenneth B. Gordon, Alice B. Gottlieb, Arthur F. Kavanaugh, Neil J. Korman, Gerald G. Krueger, Craig L. Leonardi, Sergio Schwartzman, Jeffrey M. Sobell, Gary E. Solomon & Melodie Young. (2012) A Delphi Consensus Approach to Challenging Case Scenarios in Moderate-to-Severe Psoriasis: Part 2. Dermatology and Therapy 2:1.
Crossref
Crossref
M. Viguier, C. Pagès, F. Aubin, E. Delaporte, V. Descamps, C. Lok, M. Beylot-Barry, J. Séneschal, L. Dubertret, J.-J. Morand, B. Dréno & H. Bachelez. (2012) Efficacy and safety of biologics in erythrodermic psoriasis: a multicentre, retrospective study. British Journal of Dermatology 167:2, pages 417-423.
Crossref
Crossref
Hideshi TORII & Hidemi NAKAGAWA. (2011) Long-term study of infliximab in Japanese patients with plaque psoriasis, psoriatic arthritis, pustular psoriasis and psoriatic erythroderma. The Journal of Dermatology 38:4, pages 321-334.
Crossref
Crossref
. 2011. British Association of Dermatologists' Management Guidelines. British Association of Dermatologists' Management Guidelines
205
317
.
Virendra N. Sehgal & Govind Srivastava. 2011. Emergency Dermatology. Emergency Dermatology
202
214
.
Rita V. Patel, Amylynne Frankel & Jacob Levitt. (2018) Treatment of Erythrodermic Psoriasis: Practical Application of the National Psoriasis Foundation Consensus Statement. Psoriasis Forum 16a:4, pages 61-66.
Crossref
Crossref
J.L. López-Estebaranz & D. Ruiz-Genao. (2010) Psoriasis pustulosa, psoriasis palmoplantar, psoriasis eritrodérmica y etanercept. Actas Dermo-Sifiliográficas 101, pages 35-39.
Crossref
Crossref
Misha Rosenbach, Sylvia Hsu, Neil J. Korman, Mark G. Lebwohl, Melodie Young, Bruce F. BeboJr.Jr. & Abby S. Van Voorhees. (2010) Treatment of erythrodermic psoriasis: From the medical board of the National Psoriasis Foundation. Journal of the American Academy of Dermatology 62:4, pages 655-662.
Crossref
Crossref
C.H. Smith, A.V. Anstey, J.N.W.N. Barker, A.D. Burden, R.J.G. Chalmers, D.A. Chandler, A.Y. Finlay, C.E.M. Griffiths, K. Jackson, N.J. McHugh, K.E. McKenna, N.J. Reynolds & A.D. Ormerod. (2009) British Association of Dermatologists’ guidelines for biologic interventions for psoriasis 2009. British Journal of Dermatology 161:5, pages 987-1019.
Crossref
Crossref
M.D.F. Takahashi, L.G.M. Castro & R. Romiti. (2007) Infliximab, as sole or combined therapy, induces rapid clearing of erythrodermic psoriasis. British Journal of Dermatology 157:4, pages 828-831.
Crossref
Crossref
E. Piqué-Duran & J.A. Pérez-Cejudo. (2007) Eritrodermia psoriásica tratada con etanercept. Actas Dermo-Sifiliográficas 98:7, pages 508-510.
Crossref
Crossref
E. Piqué-Duran & J.A. Pérez-Cejudo. (2007) Psoriatic Erythroderma Treated with Etanercept. Actas Dermo-Sifiliográficas (English Edition) 98:7, pages 508-510.
Crossref
Crossref
M. Esposito, A. Mazzotta, C. de Felice, M. Papoutsaki & S. Chimenti. (2006) Treatment of erythrodermic psoriasis with etanercept. British Journal of Dermatology 155:1, pages 156-159.
Crossref
Crossref
Sanjay M Rajpara, Anthony D Ormerod & Pick N Woo. (2006) Biological treatments for psoriasis. Therapy 3:3, pages 425-436.
Crossref
Crossref
Noah Scheinfeld. 2006. TNF-alpha Inhibitors. TNF-alpha Inhibitors
83
99
.
C.H. Smith, A.V. Anstey, J.N.W.N. Barker, A.D. Burden, R.J.G. Chalmers, D. Chandler, A.Y. Finlay, C.E.M. Grifitths, K. Jackson, N.J. McHugh, K.E. McKenna, N.J. Reynolds & A.D. Ormerod. (2005) British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005. British Journal of Dermatology 153:3, pages 486-497.
Crossref
Crossref
Marti Jill Rothe, Megan L. Bernstein & Jane M. Grant-Kels. (2005) Life-threatening erythroderma: diagnosing and treating the “red man”. Clinics in Dermatology 23:2, pages 206-217.
Crossref
Crossref
Samuel L. Moschella. (2007) Is There a Role for Tumor Necrosis Factor‐α Inhibitors and Especially Thalidomide in Dermatology?. SKINmed: Dermatology for the Clinician 4:1, pages 24-32.
Crossref
Crossref
Richard Groves. (2004) Cytokine and anti-cytokine therapy in the treatment of inflammatory skin disease. Cytokine 28:4-5, pages 162-166.
Crossref
Crossref
Laura Winterfield & Alan Menter. (2004) Psoriasis and its treatment with infliximab-mediated tumor necrosis factor α blockade. Dermatologic Clinics 22:4, pages 437-447.
Crossref
Crossref
W. Sterry, J. Barker, W.-H. Boehncke, J.D. Bos, S. Chimenti, E. Christophers, M. De La Brassinne, C. Ferrandiz, C. Griffiths, A. Katsambas, K. Kragballe, C. Lynde, A. Menter, J.-P. Ortonne, K. Papp, J. Prinz, B. Rzany, J. Ronnevig, J.-H. Saurat, M. Stahle, F.M. Stengel, P. Van De Kerkhof & J. Voorhees. (2004) Biological therapies in the systemic management of psoriasis: International Consensus Conference. British Journal of Dermatology 151:s69, pages 3-17.
Crossref
Crossref